Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.

Porru M, Pompili L, Caruso C, Biroccio A, Leonetti C.

J Exp Clin Cancer Res. 2018 Mar 13;37(1):57. doi: 10.1186/s13046-018-0719-1.

2.

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Pompili L, Leonetti C, Biroccio A, Salvati E.

J Exp Clin Cancer Res. 2017 Dec 22;36(1):189. doi: 10.1186/s13046-017-0657-3. Review.

3.

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.

Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matía García V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M.

EMBO Mol Med. 2017 Oct;9(10):1398-1414. doi: 10.15252/emmm.201607446.

4.

Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.

Salvati E, Botta L, Amato J, Di Leva FS, Zizza P, Gioiello A, Pagano B, Graziani G, Tarsounas M, Randazzo A, Novellino E, Biroccio A, Cosconati S.

J Med Chem. 2017 May 11;60(9):3626-3635. doi: 10.1021/acs.jmedchem.6b01563. Epub 2017 May 1.

PMID:
28445046
5.

Tandem application of ligand-based virtual screening and G4-OAS assay to identify novel G-quadruplex-targeting chemotypes.

Musumeci D, Amato J, Zizza P, Platella C, Cosconati S, Cingolani C, Biroccio A, Novellino E, Randazzo A, Giancola C, Pagano B, Montesarchio D.

Biochim Biophys Acta. 2017 May;1861(5 Pt B):1341-1352. doi: 10.1016/j.bbagen.2017.01.024. Epub 2017 Jan 24.

PMID:
28130159
6.

SIRT6 interacts with TRF2 and promotes its degradation in response to DNA damage.

Rizzo A, Iachettini S, Salvati E, Zizza P, Maresca C, D'Angelo C, Benarroch-Popivker D, Capolupo A, Del Gaudio F, Cosconati S, Di Maro S, Merlino F, Novellino E, Amoreo CA, Mottolese M, Sperduti I, Gilson E, Biroccio A.

Nucleic Acids Res. 2017 Feb 28;45(4):1820-1834. doi: 10.1093/nar/gkw1202.

7.

Patient-derived xenografts: a relevant preclinical model for drug development.

Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C.

J Exp Clin Cancer Res. 2016 Dec 5;35(1):189. Review.

8.

EMICORON: A multi-targeting G4 ligand with a promising preclinical profile.

Porru M, Zizza P, Franceschin M, Leonetti C, Biroccio A.

Biochim Biophys Acta. 2017 May;1861(5 Pt B):1362-1370. doi: 10.1016/j.bbagen.2016.11.010. Epub 2016 Nov 9. Review.

PMID:
27838395
9.

The telomeric protein AKTIP interacts with A- and B-type lamins and is involved in regulation of cellular senescence.

Burla R, Carcuro M, Torre ML, Fratini F, Crescenzi M, D'Apice MR, Spitalieri P, Raffa GD, Astrologo L, Lattanzi G, Cundari E, Raimondo D, Biroccio A, Gatti M, Saggio I.

Open Biol. 2016 Aug;6(8). pii: 160103. doi: 10.1098/rsob.160103.

10.

A bimodal fluorescent and photocytotoxic naphthalene diimide for theranostic applications.

Salvati E, Doria F, Manoli F, D'Angelo C, Biroccio A, Freccero M, Manet I.

Org Biomol Chem. 2016 Jul 26;14(30):7238-49. doi: 10.1039/c6ob00987e.

PMID:
27383473
11.

Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells.

Micheli E, Altieri A, Cianni L, Cingolani C, Iachettini S, Bianco A, Leonetti C, Cacchione S, Biroccio A, Franceschin M, Rizzo A.

Biochimie. 2016 Jun;125:223-31. doi: 10.1016/j.biochi.2016.04.008. Epub 2016 Apr 13.

PMID:
27086081
12.

Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.

Zimmer J, Tacconi EMC, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.

Mol Cell. 2016 Feb 4;61(3):449-460. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.

13.

Anacardic acid and thyroid hormone enhance cardiomyocytes production from undifferentiated mouse ES cells along functionally distinct pathways.

Re A, Nanni S, Aiello A, Granata S, Colussi C, Campostrini G, Spallotta F, Mattiussi S, Pantisano V, D'Angelo C, Biroccio A, Rossini A, Barbuti A, DiFrancesco D, Trimarchi F, Pontecorvi A, Gaetano C, Farsetti A.

Endocrine. 2016 Sep;53(3):681-8. doi: 10.1007/s12020-015-0751-2. Epub 2015 Nov 7.

PMID:
26547215
14.

Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance.

Zizza P, Cingolani C, Artuso S, Salvati E, Rizzo A, D'Angelo C, Porru M, Pagano B, Amato J, Randazzo A, Novellino E, Stoppacciaro A, Gilson E, Stassi G, Leonetti C, Biroccio A.

Nucleic Acids Res. 2016 Feb 29;44(4):1579-90. doi: 10.1093/nar/gkv1122. Epub 2015 Oct 27.

15.

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer.

Porru M, Artuso S, Salvati E, Bianco A, Franceschin M, Diodoro MG, Passeri D, Orlandi A, Savorani F, D'Incalci M, Biroccio A, Leonetti C.

Mol Cancer Ther. 2015 Nov;14(11):2541-51. doi: 10.1158/1535-7163.MCT-15-0253. Epub 2015 Aug 24.

16.

AKTIP/Ft1, a New Shelterin-Interacting Factor Required for Telomere Maintenance.

Burla R, Carcuro M, Raffa GD, Galati A, Raimondo D, Rizzo A, La Torre M, Micheli E, Ciapponi L, Cenci G, Cundari E, Musio A, Biroccio A, Cacchione S, Gatti M, Saggio I.

PLoS Genet. 2015 Jun 25;11(6):e1005167. doi: 10.1371/journal.pgen.1005167. eCollection 2015 Jun.

17.

Erratum: identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.

Rizzo A, Iachettini S, Zizza P, Cingolani C, Porru M, Artuso S, Stevens M, Hummersone M, Biroccio A, Salvati E, Leonetti C.

J Exp Clin Cancer Res. 2015 Feb 5;34:9. doi: 10.1186/s13046-014-0101-x. No abstract available.

18.

Looking for efficient G-quadruplex ligands: evidence for selective stabilizing properties and telomere damage by drug-like molecules.

Pagano B, Amato J, Iaccarino N, Cingolani C, Zizza P, Biroccio A, Novellino E, Randazzo A.

ChemMedChem. 2015 Apr;10(4):640-9. doi: 10.1002/cmdc.201402552. Epub 2015 Feb 18.

PMID:
25694275
19.

A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds.

Salvati E, Rizzo A, Iachettini S, Zizza P, Cingolani C, D'Angelo C, Porru M, Mondello C, Aiello A, Farsetti A, Gilson E, Leonetti C, Biroccio A.

Nucleic Acids Res. 2015 Feb 18;43(3):1759-69. doi: 10.1093/nar/gkv006. Epub 2015 Jan 23.

20.

Identification of novel interactors of human telomeric G-quadruplex DNA.

Pagano B, Margarucci L, Zizza P, Amato J, Iaccarino N, Cassiano C, Salvati E, Novellino E, Biroccio A, Casapullo A, Randazzo A.

Chem Commun (Camb). 2015 Feb 18;51(14):2964-7. doi: 10.1039/c4cc07231f.

PMID:
25594748
21.

Shading the TRF2 recruiting function: a new horizon in drug development.

Di Maro S, Zizza P, Salvati E, De Luca V, Capasso C, Fotticchia I, Pagano B, Marinelli L, Gilson E, Novellino E, Cosconati S, Biroccio A.

J Am Chem Soc. 2014 Dec 3;136(48):16708-11. doi: 10.1021/ja5080773. Epub 2014 Nov 19.

PMID:
25393214
22.

Design and synthesis of a new dimeric xanthone derivative: enhancement of G-quadruplex selectivity and telomere damage.

Franceschin M, Nocioni D, Biroccio A, Micheli E, Cacchione S, Cingolani C, Venditti A, Zizza P, Bianco A, Altieri A.

Org Biomol Chem. 2014 Dec 21;12(47):9572-82. doi: 10.1039/c4ob01658k. Epub 2014 Nov 3.

PMID:
25363232
23.

Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities.

Rizzo A, Iachettini S, Zizza P, Cingolani C, Porru M, Artuso S, Stevens M, Hummersone M, Biroccio A, Salvati E, Leonetti C.

J Exp Clin Cancer Res. 2014 Oct 6;33:81. doi: 10.1186/s13046-014-0081-x. Erratum in: J Exp Clin Cancer Res. 2015;34:9.

24.

Bis-indole derivatives with antitumor activity turn out to be specific ligands of human telomeric G-quadruplex.

Amato J, Iaccarino N, Pagano B, Morigi R, Locatelli A, Leoni A, Rambaldi M, Zizza P, Biroccio A, Novellino E, Randazzo A.

Front Chem. 2014 Jul 24;2:54. doi: 10.3389/fchem.2014.00054. eCollection 2014.

25.

A novel pathway links telomeres to NK-cell activity: Implications for immunotherapy.

Cherfils-Vicini J, Zizza P, Gilson E, Biroccio A.

Oncoimmunology. 2014 Jan 1;3(1):e27358.

26.

Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis.

Salvati E, Zizza P, Rizzo A, Iachettini S, Cingolani C, D'Angelo C, Porru M, Randazzo A, Pagano B, Novellino E, Pisanu ME, Stoppacciaro A, Spinella F, Bagnato A, Gilson E, Leonetti C, Biroccio A.

Nucleic Acids Res. 2014 Mar;42(5):2945-57. doi: 10.1093/nar/gkt1289. Epub 2013 Dec 11. Erratum in: Nucleic Acids Res. 2014 Dec 16;42(22):14083.

27.

On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts.

Iachettini S, Stevens MF, Frigerio M, Hummersone MG, Hutchinson I, Garner TP, Searle MS, Wilson DW, Munde M, Nanjunda R, D'Angelo C, Zizza P, Rizzo A, Cingolani C, De Cicco F, Porru M, D'Incalci M, Leonetti C, Biroccio A, Salvati E.

J Exp Clin Cancer Res. 2013 Sep 19;32:68. doi: 10.1186/1756-9966-32-68.

28.

Exploring the chemical space of G-quadruplex binders: discovery of a novel chemotype targeting the human telomeric sequence.

Di Leva FS, Zizza P, Cingolani C, D'Angelo C, Pagano B, Amato J, Salvati E, Sissi C, Pinato O, Marinelli L, Cavalli A, Cosconati S, Novellino E, Randazzo A, Biroccio A.

J Med Chem. 2013 Dec 12;56(23):9646-54. doi: 10.1021/jm401185b. Epub 2013 Nov 27.

PMID:
24256368
29.

TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E.

Nat Cell Biol. 2013 Jul;15(7):818-28. doi: 10.1038/ncb2774. Epub 2013 Jun 23.

PMID:
23792691
30.

β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.

Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, Salvati E, Biroccio AM, Natali PG, Bagnato A.

Oncogene. 2013 Oct 17;32(42):5066-77. doi: 10.1038/onc.2012.527. Epub 2012 Dec 3.

PMID:
23208497
31.

Aromatic core extension in the series of N-cyclic bay-substituted perylene G-quadruplex ligands: increased telomere damage, antitumor activity, and strong selectivity for neoplastic over healthy cells.

Franceschin M, Rizzo A, Casagrande V, Salvati E, Alvino A, Altieri A, Ciammaichella A, Iachettini S, Leonetti C, Ortaggi G, Porru M, Bianco A, Biroccio A.

ChemMedChem. 2012 Dec;7(12):2144-54. doi: 10.1002/cmdc.201200348. Epub 2012 Oct 24.

PMID:
23097341
32.

Shooting for selective druglike G-quadruplex binders: evidence for telomeric DNA damage and tumor cell death.

Cosconati S, Rizzo A, Trotta R, Pagano B, Iachettini S, De Tito S, Lauri I, Fotticchia I, Giustiniano M, Marinelli L, Giancola C, Novellino E, Biroccio A, Randazzo A.

J Med Chem. 2012 Nov 26;55(22):9785-92. doi: 10.1021/jm301019w. Epub 2012 Oct 18.

PMID:
23057850
33.

Methods of studying telomere damage induced by quadruplex-ligand complexes.

Rizzo A, Salvati E, Biroccio A.

Methods. 2012 May;57(1):93-9. doi: 10.1016/j.ymeth.2012.02.010. Epub 2012 Mar 4. Review.

PMID:
22410593
34.

Targeted therapy for brain tumours: role of PARP inhibitors.

Leonetti C, Biroccio A, Graziani G, Tentori L.

Curr Cancer Drug Targets. 2012 Mar;12(3):218-36. Review.

PMID:
22268386
35.

Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.

Spugnini EP, Biroccio A, De Mori R, Scarsella M, D'Angelo C, Baldi A, Leonetti C.

J Transl Med. 2011 Jul 28;9:125. doi: 10.1186/1479-5876-9-125.

36.

DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.

Biroccio A, Porru M, Rizzo A, Salvati E, D'Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi G, Pisano C, Zunino F, Leonetti C.

Clin Cancer Res. 2011 Apr 15;17(8):2227-36. doi: 10.1158/1078-0432.CCR-10-3033. Epub 2011 Feb 25.

37.

Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.

Stoppoloni D, Salvatori L, Biroccio A, D'Angelo C, Muti P, Verdina A, Sacchi A, Vincenzi B, Baldi A, Galati R.

J Thorac Oncol. 2011 Mar;6(3):583-91. doi: 10.1097/JTO.0b013e31820cdd6f.

38.

N-cyclic bay-substituted perylene G-quadruplex ligands have selective antiproliferative effects on cancer cells and induce telomere damage.

Casagrande V, Salvati E, Alvino A, Bianco A, Ciammaichella A, D'Angelo C, Ginnari-Satriani L, Serrilli AM, Iachettini S, Leonetti C, Neidle S, Ortaggi G, Porru M, Rizzo A, Franceschin M, Biroccio A.

J Med Chem. 2011 Mar 10;54(5):1140-56. doi: 10.1021/jm1013665. Epub 2011 Jan 31.

PMID:
21280624
39.

Smad-interacting protein-1 and microRNA 200 family define a nitric oxide-dependent molecular circuitry involved in embryonic stem cell mesendoderm differentiation.

Rosati J, Spallotta F, Nanni S, Grasselli A, Antonini A, Vincenti S, Presutti C, Colussi C, D'Angelo C, Biroccio A, Farsetti A, Capogrossi MC, Illi B, Gaetano C.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):898-907. doi: 10.1161/ATVBAHA.110.214478. Epub 2011 Jan 13.

PMID:
21233447
40.

PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.

Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, Tentori L, Graziani G, D'Incalci M, Stevens MF, Orlandi A, Passeri D, Gilson E, Zupi G, Leonetti C, Biroccio A.

Oncogene. 2010 Nov 25;29(47):6280-93. doi: 10.1038/onc.2010.344. Epub 2010 Aug 30.

PMID:
20802516
41.

TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage.

Ye J, Lenain C, Bauwens S, Rizzo A, Saint-Léger A, Poulet A, Benarroch D, Magdinier F, Morere J, Amiard S, Verhoeyen E, Britton S, Calsou P, Salles B, Bizard A, Nadal M, Salvati E, Sabatier L, Wu Y, Biroccio A, Londoño-Vallejo A, Giraud-Panis MJ, Gilson E.

Cell. 2010 Jul 23;142(2):230-42. doi: 10.1016/j.cell.2010.05.032.

42.

Antiproliferative effect of Aurora kinase targeting in mesothelioma.

Crispi S, Fagliarone C, Biroccio A, D'Angelo C, Galati R, Sacchi A, Vincenzi B, Baldi A, Verdina A.

Lung Cancer. 2010 Dec;70(3):271-9. doi: 10.1016/j.lungcan.2010.03.005. Epub 2010 Apr 3.

PMID:
20371132
43.

Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.

Chevanne M, Zampieri M, Caldini R, Rizzo A, Ciccarone F, Catizone A, D'Angelo C, Guastafierro T, Biroccio A, Reale A, Zupi G, Caiafa P.

J Cell Physiol. 2010 Feb;222(2):401-10. doi: 10.1002/jcp.21964.

PMID:
19890834
44.

Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway.

Rizzo A, Salvati E, Porru M, D'Angelo C, Stevens MF, D'Incalci M, Leonetti C, Gilson E, Zupi G, Biroccio A.

Nucleic Acids Res. 2009 Sep;37(16):5353-64. doi: 10.1093/nar/gkp582. Epub 2009 Jul 13.

45.

Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11. doi: 10.1073/pnas.0807158106. Epub 2009 Feb 6.

46.

G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D'Incalci M, Staszewsky L, Frapolli R, Stevens MF, Stoppacciaro A, Mottolese M, Antoniani B, Gilson E, Zupi G, Biroccio A.

Clin Cancer Res. 2008 Nov 15;14(22):7284-91. doi: 10.1158/1078-0432.CCR-08-0941.

47.

Glutathione transferases and glutathionylated hemoglobin in workers exposed to low doses of 1,3-butadiene.

Primavera A, Fustinoni S, Biroccio A, Ballerini S, Urbani A, Bernardini S, Federici G, Capucci E, Manno M, Lo Bello M.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3004-12. doi: 10.1158/1055-9965.EPI-08-0443.

48.

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect.

Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens MF, D'Incalci M, Blasco M, Chiorino G, Bauwens S, Horard B, Gilson E, Stoppacciaro A, Zupi G, Biroccio A.

J Clin Invest. 2007 Nov;117(11):3236-47.

49.

Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.

Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G.

Prostate. 2007 Sep 15;67(13):1475-85.

PMID:
17654511
50.

Gamma-glutamylcysteine synthetase mediates the c-Myc-dependent response to antineoplastic agents in melanoma cells.

Benassi B, Zupi G, Biroccio A.

Mol Pharmacol. 2007 Oct;72(4):1015-23. Epub 2007 Jul 12.

Supplemental Content

Loading ...
Support Center